{"id":"amlodipine-losartan-chlorthalidone","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Peripheral edema"},{"rate":"3-7","effect":"Dizziness"},{"rate":"2-5","effect":"Fatigue"},{"rate":"2-5","effect":"Hypokalemia"},{"rate":"1-3","effect":"Hyperuricemia"},{"rate":"2-4","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine blocks L-type calcium channels in vascular smooth muscle to cause vasodilation. Losartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release. Chlorthalidone is a thiazide-like diuretic that reduces blood volume and sodium reabsorption. Together, these agents provide synergistic blood pressure reduction for patients requiring multi-drug therapy.","oneSentence":"This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuresis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:11.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (marketed combination therapy)"}]},"trialDetails":[{"nctId":"NCT05370599","phase":"PHASE2","title":"Hypertension in Young Adults Trial","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2022-04-15","conditions":"Hypertension","enrollment":36},{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":"Hypertension, Vascular Stiffness, Aging","enrollment":228},{"nctId":"NCT03666351","phase":"PHASE4","title":"Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-18","conditions":"Aortic Stenosis, Aortic Regurgitation, Hypertension","enrollment":128},{"nctId":"NCT05462535","phase":"","title":"An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-02-26","conditions":"Hypertension,Essential","enrollment":4785},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT02121041","phase":"NA","title":"Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study","status":"COMPLETED","sponsor":"Anthony J Viera, MD, MPH","startDate":"2014-05","conditions":"Hypertension","enrollment":28},{"nctId":"NCT02232880","phase":"PHASE2","title":"Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2014-08","conditions":"Hypertension","enrollment":1},{"nctId":"NCT02916602","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-04","conditions":"Hypertension","enrollment":340},{"nctId":"NCT02387554","phase":"PHASE1","title":"Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-08","conditions":"Hypertension(HTN)","enrollment":33},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amosartan Plus Tab. 5/100/12.5 mg"],"phase":"marketed","status":"active","brandName":"Amlodipine/Losartan/Chlorthalidone","genericName":"Amlodipine/Losartan/Chlorthalidone","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuresis. Used for Hypertension (marketed combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}